Sponsor: Boston Biomedical, Inc.
First line treatment adding Napabucasin to standard of care chemotherapy combination Nab-Paclitaxel and Gemcitibine for patients with metastatic pancreatic cancer. Napabucasin is a novel, orally administered agent that works by inhibiting the renewal and survival of cancer stem cells.